Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q3 2026 data is still coming in (13F filing deadline: Nov 16, 2026), so these numbers are incomplete.
Q3 2026 vs. Q2 2026
How the institutions holding Viridian Therapeutics, Inc. changed between Q2 2026 and Q3 2026.
All holders in Q3 2026All holders in Q2 2026
| Measure | Q2 2026 | Of which not filed for Q3 2026 | Q3 2026 | Change |
|---|---|---|---|---|
| Holders | 214 | 213 | 0 | −1 |
| Shares | 136.0M | 136.0M | 0 | −30.0K (−100.0%) |
| Value | $2.50B | $2.50B | $0 | −$551.1K (−100.0%) |
213 institutions that held it in Q2 2026 haven't filed for Q3 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (0)
Institutions that held Viridian Therapeutics, Inc. at the end of Q3 2026 but not at the end of Q2 2026.
None.
Sold out (1)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2026 and filed for Q3 2026 without it.
| Institution | Shares, Q2 2026 | Value, Q2 2026 |
|---|---|---|
| Doliver Advisors, LP | 30,000 | $551.1K |
Not filed for Q3 2026 yet (213)
Institutions that held Viridian Therapeutics, Inc. at the end of Q2 2026 and haven't filed a 13F for Q3 2026. Not filing isn't selling, so they aren't counted as sold out.
Showing the largest 100 of 213 by value.